Table 1.
Round One |
Steering group consensus | Round Two |
Final recommendations | ||||||
---|---|---|---|---|---|---|---|---|---|
Clinical Domain | Total | Accepted | Revision* | Rejected | New statements included† | Total | Accepted | Rejected‡ | Total accepted |
Assessment | 8 | 6 | 2 | 0 | 1 | 3 | 3 | 0 | 9 |
OAT drug choice and optimal dosing | 5 | 2 | 3 | 0 | 1 | 4 | 1 | 3 | 3 |
Drug testing | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | 0 |
Take-away doses | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Overdose prevention | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
E-Prescriptions | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Total | 19 | 12 | 7 | 0 | 2 | 9 | 4 | 5 | 16 |
Required revision, rewording or refinement.
The project steering group developed new statements to be included in round two based on comments/suggestions made by panel members during the first round.
Where consensus was not reached at round two, statements were rejected.